{"id":"W3160346821","doi":"10.1038/s41375-021-01260-y","title":"Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update","year":2021,"lang":"en","type":"article","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Nilotinib; Medicine; Myeloid leukemia; Internal medicine; Adverse effect; Tyrosine-kinase inhibitor; Imatinib; Surgery; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001410588,0.0008242473,0.001061286,0.0002798557,0.0001175856,0.00006775834,0.0003376862,0.0004382186,0.004161248],"category_scores_gemma":[0.0001091758,0.0006567221,0.0002511049,0.000711498,0.0001498086,0.0003210816,0.00028546,0.0006155435,0.0004982607],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.02762262,"about_ca_system_score_gemma":0.006498119,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002189483,"about_ca_topic_score_gemma":0.002054048,"domain_scores_codex":[0.9958227,0.0001368758,0.0008236116,0.001343007,0.0007752233,0.001098597],"domain_scores_gemma":[0.9965981,0.00009528576,0.0002564456,0.002269156,0.0002416959,0.0005393286],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003237612,0.0006824705,0.9706334,0.0003814732,0.0003886624,0.003281314,0.0002576626,0.00007959972,0.001299363,0.00002193008,0.0009837836,0.01875274],"study_design_scores_gemma":[0.0498705,0.001888077,0.9208847,0.001079511,0.0003824569,0.0001811013,0.00002316636,0.00009089278,0.01926709,0.00003450493,0.005613945,0.0006840781],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944314,0.001593244,0.00001918991,0.0002753673,0.0002920731,0.001110138,0.000116849,0.0002040651,0.001957648],"genre_scores_gemma":[0.9836689,0.0004075309,0.001242214,0.0005743094,0.0004596808,0.0002209785,0.00153702,0.0001996343,0.0116897],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04974872,"threshold_uncertainty_score":0.9995884,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.009310910288651317,"score_gpt":0.2404248487691427,"score_spread":0.2311139384804914,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}